Related Experiment Video

Updated: Oct 2, 2025

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
12:32

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds

Published on: January 23, 2018

12.5K

mPGES-2 blockade antagonizes β-cell senescence to ameliorate diabetes by acting on NR4A1

Dandan Zhong1, Zhikang Wan1,2, Jie Cai1,3

  • 1Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, P. R. China.

Nature Metabolism
|March 1, 2022
PubMed

Insights

Microsomal prostaglandin E synthase-2 (mPGES-2) deficiency improves beta-cell function and glucose homeostasis in aging-related diabetes models. Blocking mPGES-2 may offer a new therapeutic strategy for diabetes.

Area of Science:

  • Endocrinology
  • Metabolism
  • Cellular Biology

Background:

  • Beta-cell dysfunction is central to type 1 and type 2 diabetes.
  • Ageing contributes to beta-cell abnormalities in type 2 diabetes through poorly understood mechanisms.

Purpose of the Study:

  • To investigate the role of microsomal prostaglandin E synthase-2 (mPGES-2) in age-related beta-cell dysfunction.
  • To explore mPGES-2 as a potential therapeutic target for diabetes.

Main Methods:

  • Utilized global mPGES-2-deficient mice, beta-cell-specific mPGES-2 knockout/overexpression models, and db/db mice.
  • Challenged mice with high-fat diets to model type 2 diabetes.
  • Investigated the PGE2-EP3-NR4A1 signaling axis and tested an mPGES-2 inhibitor (SZ0232).

Main Results:

  • mPGES-2 deficiency improved beta-cell identity, reduced senescence, enhanced insulin secretion, and improved glucose homeostasis.
  • Deletion of mPGES-2 protected against diet-induced and genetic type 2 diabetes.
  • mPGES-2 inhibition via SZ0232 mimicked these protective effects.

Conclusions:

  • mPGES-2 promotes age-associated beta-cell senescence and dysfunction through the PGE2-EP3-NR4A1 pathway.
  • Pharmacological inhibition of mPGES-2 presents a promising therapeutic approach for age-related beta-cell dysfunction and diabetes.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

559
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.9K

Related Concept Videos

Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
14.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
457
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.5K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
279
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.0K